Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Breast and Gynecologic Cancer
Sponsor
Northwestern University
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT00952731
This randomized phase II trial is studying 4-hydroxytamoxifen to see how well it works compared with tamoxifen citrate in treating women with newly diagnosed ductal breast carcinoma in situ. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells. It is not yet known whether topical tamoxifen causes less damage to normal tissue than systemic tamoxifen in treating patients with ductal carcinoma in situ.
Intervention
oral placebo, afimoxifene, tamoxifen citrate, placebo gel
Condition
Ductal Breast Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
Investigators
Seema Khan